Table 5.
Median (25% quartile–75% quartile) of (CL/F) and renal (CLR) clearances of methotrexate (MTX) and renal clearance of 7-hydroxymethotrexate (7-OHMTX) in psoriatic patients following oral administration of 2.5 mg (5.5 µmol) and 5 mg (11 µmol) methotrexate. The drug was administered once a week with the weekly dose divided into three aliquots given at 12 h intervals. Clearances were estimated after the third doses administered at weeks 1 and 13.
| Week 1 | Week 13 | |||
|---|---|---|---|---|
| Dose | 2.5 mg | 5 mg | 2.5 mg | 5 mg |
| CL/F (l h−1) MTX | 9.2 (6.6–11.3) | 10.6 (9.7–12.8) | 10.5 (7.7–11.2) | 11.9 (9.2–14.7) |
| CLR (l h−1) MTX | 7.1 (4.6–9.3) | 8.8 (6.5–10.0) | 6.6 (5.7–6.9) | 8.8 (7.6–10.0) |
| CLR (l h−1) 7-OH MTX | 0.78 (0.57–1.10) | 0.64 (0.50–0.86) | 0.80 (0.66–0.90) | 0.71 (0.54–1.05) |